The primary focus for the use of Кратал is generally applied to situations involving conditions where nervous tension intersects with cardiovascular function, offering supportive relief for both domains. Its components are recognized for providing symptomatic relief across these dual areas.

The preparation is commonly used to help with symptomatic relief for functional heart complaints (such as mild palpitations and functional tachycardia), alongside nervous excitability, unease, and stress-related physical manifestations. The preparation may assist with maintaining functional stability, and contributes to easing the overall symptom load during periods of heightened symptoms, supporting patients through difficult episodes.

The preparation is commonly used in conditions where functional stability becomes affected, and may be relevant as an adjunct in established conditions like chronic ischemic heart disease or chronic heart failure. This application provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Nervous Cardiac Symptoms The medicine is relevant for easing symptoms related to heightened physiological activity, and may assist with managing symptoms that create noticeable physiological strain, particularly when mild palpitations and restlessness appear suddenly or fluctuate.

Eligibility Map: Who can and cannot use Кратал — Official Component-Based Information

This eligibility information for the combination product Krasatal is synthesized from authoritative sources on its active ingredients: Taurine, Hawthorn (Crataegus), and Motherwort.

Eligibility scope

Connection to the overall eligibility profile: The regulatory profile for Krasatal is defined primarily by the known pharmacological actions and interactions of its active components. Eligibility is constrained due to the potential for uterine stimulation in pregnant women, which constitutes a contraindication in that population. Use is further restricted or requires special consideration when co-administered with prescribed cardiovascular or sedative medications, necessitating a detailed clinical review before initiation.

Interactions with other medicines and products

The final section focuses exclusively on documented interaction patterns derived from regulatory assessments of Кратал's active components, Crataegi Fructus and Leonuri Herba. The primary interaction profile is defined by pharmacodynamic reinforcement. Due to the established sedative properties of the Leonuri Herba component, co-administration with other medicinal products that cause Central Nervous System (CNS) depression carries a risk of additive effects, such as increased drowsiness or sedation. This category includes certain anxiolytics, hypnotics, and other sedatives. The consumption of Alcohol (ethanol) also falls within this risk category and may reinforce the CNS depressant effects of the medicine.

The regulatory monograph for the Crataegi Fructus component officially states that no interactions with other medicinal products have been reported for its traditional use. This absence of documented findings extends to specific pharmacokinetic or metabolic interactions (e.g., CYP- or transporter-mediated effects) for both active ingredients. The regulatory documents do not designate any medicinal products as formally contraindicated combinations (prohibited co-administration). Furthermore, there are no official instructions mandating timing separation (e.g., administering doses a specific number of hours apart) with other substances. The interaction framework is therefore built around the need to manage the potential additive sedative effect.

How Кратал Works: Pharmacodynamic Mechanism

The mechanism of action involves three primary biological domains. First, the drug influences cellular bioenergetics by modulating mitochondrial function and managing cellular oxidative load through the scavenging of Reactive Oxygen Species (ROS), supported by the influence on native antioxidant enzyme activity. Components also inhibit specific enzymes involved in lipid and sterol processing. This action influences the maintenance of metabolic pathways and membrane integrity within myocardial and neuronal tissues.

Second, the drug acts on cardiac electrophysiology by modulating ion channels to influence the refractory period of the myocardial cell membrane. It also acts peripherally by affecting the release of mediators that promote vasodilation. This action influences the characteristics of cardiac excitation and affects local blood flow parameters. Third, components interact with the Central Nervous System (CNS), particularly by influencing GABAergic pathways, which alters neural activity and signaling parameters. This leads to an alteration in the systemic physiological response to various stimuli.

How Кратал is Used: Official Administration Guidelines

Кратал (Cratal) is a combination herbal product administered in a standardized pattern, which establishes the required route, dose, frequency, and duration of use for adult patients.

The medicine is supplied as a tablet and its use is confined to the oral route of administration. The recommended daily regimen is structured as a divided dose intended for consistent intervals throughout the day.

Official Usage Parameters for Adults

Treatment Duration and Patient Group

The usage protocol specifies that Кратал is for adults (18 years and older). The medicine is typically taken in defined therapeutic courses or cycles. The standard duration for a single course of use is between three and four weeks. Continuation beyond this period is determined by a reassessment of the patient's condition.

This regimen defines a procedural structure where the medicine is integrated into the patient's routine by defining the route, the three-times-daily frequency, and the pre-meal timing, all of which establish the formal conditions for its administration.

Research Evidence / Overview of Studies for Кратал

Evidence for Functional Nervous Cardiac Complaints and Mild Anxiety Symptoms

The research base for functional nervous cardiac complaints involves studies that have explored both the Hawthorn and Motherwort components of Кратал individually, as well as in combination with other herbs. Researchers in these trials were primarily interested in outcomes related to systemic or functional imbalance, such as patient-reported measures of nervous tension, general unease, and subjective changes in mild heart symptoms. These studies monitored how symptoms evolved in the observed populations, with many relying on traditional use documentation to help contextualize how patients reported their experience with these extracts.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations, with some research highlighting changes measured during the study period, such as shifts in standardized anxiety scale scores. Findings were mixed across studies due to differences in the specific extracts used and the exact outcomes monitored. Evidence contributes to understanding symptom patterns, but the certainty remains low when specifically considering the fixed combination of Hawthorn and Motherwort found in Кратал. Long-term effects on outcomes related to systemic or functional imbalance are not fully established by the existing body of research.

Evidence Supporting Use in Chronic Heart Failure (NYHA Class II and III)

Research examining standardized mono-preparations of Hawthorn extract, one of the components of Кратал, includes large randomized controlled trials (RCTs) and comprehensive meta-analyses. This research focused on populations diagnosed with mild to moderate chronic heart failure (NYHA Class II and III) who were already receiving conventional medical treatment. Research monitored physiological strain or stress, with studies examining outcomes reflecting daily functioning or activity level, such as maximal exercise capacity (measured by workload or distance walked) and changes in heart function measurements like ejection fraction.

Studies monitored outcomes related to systemic or functional imbalance, such as maximal exercise capacity, with research highlighting changes measured during the study period; trials also reported how symptoms evolved in the observed populations, including outcomes describing episodic or acute changes such as fatigue and shortness of breath. Findings describe patterns observed in the studies where some trials monitored long-term endpoints, including survival rates and the frequency of cardiac events. This research describes outcomes related to the standardized Hawthorn extracts and not the specific Hawthorn and Motherwort combination. This evidence contributes to the broader evidence landscape for conditions marked by functional limitations; research highlights that the findings largely pertain to the Hawthorn component alone.

Key Research Gaps and Uncertainties

Despite the available evidence base, several research limitations frame the understanding of Кратал. The most significant gap is the lack of specific, large-scale randomized controlled trials that rigorously examine the precise fixed combination of Hawthorn and Motherwort found in Кратал. Evidence derived from settings with varying symptom burdens show patterns related to Hawthorn mono-extracts, and comparative evidence is lacking for the specific Hawthorn + Motherwort formulation in Кратал. Secondly, evidence quality varies across studies, and sample sizes were modest in many of the trials focused on functional nervous complaints. Finally, there is limited information for long-term outcomes and durability for the specific dual-herb preparation. Research provides context but not individual predictions, and studies help show what has been observed so far, highlighting what is known—and what is still uncertain.

Common questions about Кратал (FAQ)

Q: What is Кратал used for?

A: Кратал is indicated for the supportive treatment of chronic heart failure and ischemic heart disease. It is also used in the management of post-myocardial infarction and post-stroke conditions as part of complex therapy.

Q: How does Кратал work?

A: The mechanism of action is thought to involve modulating cellular metabolism. Specifically, research suggests it may help optimize energy use within heart muscle cells under conditions of insufficient oxygen supply.

Q: Is Кратал the same as Trimetazidine?

A: Кратал is a combination medicine. It contains the active ingredients Trimetazidine dihydrochloride, Hawthorn extract, and Taurine. Trimetazidine is one component, and the other ingredients are included to potentially complement its metabolic actions.

Q: Who should not take Кратал?

A: Contraindications typically include known hypersensitivity to the active substances or any excipients. It is generally not recommended for patients with severe kidney impairment or Parkinson's disease, or pregnant and breastfeeding women. A healthcare professional should determine appropriateness.

Q: What are the side effects of Кратал?

A: As with many medications, some individuals may experience side effects. Commonly reported effects can include digestive issues, headache, and dizziness. Serious adverse effects are rare, and patients should report any concerning symptoms to a doctor.

How to Store and Dispose of Кратал (Official Regulatory Information)

The storage and handling requirements for Кратал are defined by official regulatory documentation, focusing on temperature control and stability after the container is opened.

Mandatory Storage and Stability Conditions

These official statements dictate that the product requires strict refrigeration once opened. The medicine's stability is specifically limited to 90 days after the container is first accessed. Current government documentation does not explicitly detail specific disposal instructions (such as returning to a pharmacy or avoiding household waste).